parallel randomized trial

S003014

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Metabolic dysfunction associated steatotic liver disease or steatohepatitisS003014

Design

Randomized: 115
Start year
Treatment: 26.07 weeks, follow-up 26.07 weeks
Countries: Ukraine (1 sites)
Sponsor: (not reported)
Eligibility: age 26 to 67; MASLD by steatometry with a cardiometabolic risk factor; no prior cardiovascular events or cirrhosis

Conduct and analysis

Blinding: not reported
Sequence generation: computer
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population: randomized
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed
A1	Standard care or no added treatment Control, lifestyle only	Mediterranean diet and at least 150 minutes weekly moderate activity; lifestyle: standard	36	36
A2	Dapagliflozin Dapagliflozin (Group IA)	Mediterranean diet and 150 min weekly moderate activity; lifestyle: standard	41	41
A3	Liraglutide 1.8 mg subcutaneous once daily Liraglutide (Group IB)	Mediterranean diet and 150 min weekly moderate activity; lifestyle: standard	38	38

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Standard care or no added treatment A1	Dapagliflozin A2	Liraglutide 1.8 mg subcutaneous once daily A3
age: 25 to 34	n	8	12	10
age: 25 to 34	percent	22.2	29.3	26.3
age: 35 to 44	n	11	13	13
age: 35 to 44	percent	30.6	31.7	34.2
age: 45 to 54	n	12	10	9
age: 45 to 54	percent	33.3	24.4	23.7
age: 55 to 67	n	5	6	6
age: 55 to 67	percent	13.9	14.6	15.8
age	mean (years)	43.3	41.7	39.6
age	sd (years)	11	10.7	11.2
bmi	mean (kg/m2)	30.95	31.61	32.16
bmi	sd (kg/m2)	3.4	3.1	4.4
female	n	11	17	8
female	percent	31	41	21
sbp	mean (mmHg)	132.5	133.7	132.2
sbp	sd (mmHg)	13.6	16.6	15.6